FDA Approves “Glowing Tumor” Imaging Drug for Lung Cancer Surgery

The U.S. FDA has approved the “glowing tumor” targeted imaging agent Cytalux (pafolacianine) for use in lung cancer surgery, following extensive clinical testing led by Penn Medicine surgeons and researchers.